請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61653
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 趙坤茂(Kun-Mao Chao) | |
dc.contributor.author | Chih-Hsin Lee | en |
dc.contributor.author | 李枝新 | zh_TW |
dc.date.accessioned | 2021-06-16T13:08:33Z | - |
dc.date.available | 2013-08-14 | |
dc.date.copyright | 2013-08-14 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-01 | |
dc.identifier.citation | Boutayeb A. The Double Burden of Communicable and Non-Communicable Diseases in Developing Countries. Trans R Soc Trop Med Hyg 2006; 100:191-9.
2. Sorensen JB, Demaio A, Ostergaard LR, Nielsen KK, Bygbjerg IB, De Courten M. Non-Communicable Diseases: Harnessing the Current Opportunities. Scand J Public Health 2012; 40:579-81. 3. Berger M, Birch LM, Conte NF. The Nephrotic Syndrome Secondary to Acute Glomerulonephritis During Falciparum Malaria. Ann Intern Med 1967; 67:1163-71. 4. Gilles HM, Hendrickse RG. Possible Aetiological Role of Plasmodium Malariae in 'Nephrotic Syndrome' in Nigerian Children. Lancet 1960; 1:806-7. 5. Gamble ME. Vesical Carcinoma Associated with Widespread Schistosomiasis. West Afr Med J 1954; 3:48-51. 6. Teres J, Guardia J, Bruguera M, Rodes J. Hepatitis-Associated Antigen and Hepatocellular Carcinoma. Lancet 1971; 2:215. 7. Yilmaz F, Uzunlar AK, Sogutcu N, Ozaydin M. Hodgkin's Disease and Association with Epstein-Barr Virus in Children in Southeast Turkey. Saudi Med J 2005; 26:571-5. 8. Dooley KE, Chaisson RE. Tuberculosis and Diabetes Mellitus: Convergence of Two Epidemics. Lancet Infect Dis 2009; 9:737-46. 9. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis. Am J Trop Med Hyg 2009; 80:634-9. 10. McNeil AJ, Yap PL, Gore SM, et al. Association of Hla Types A1-B8-Dr3 and B27 with Rapid and Slow Progression of Hiv Disease. QJM 1996; 89:177-85. 11. Neumann-Haefelin C, McKiernan S, Ward S, et al. Dominant Influence of an Hla-B27 Restricted Cd8+ T Cell Response in Mediating Hcv Clearance and Evolution. Hepatology 2006; 43:563-72. 12. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356:775-89. 13. Bureau of National Health Insurance. The National Health Insurance Statistics. Available at: http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&webdata_id=1942&WD_ID=296. 14. World Health Organization. Global Tuberculosis Report: World Health Organization, 2012. 15. Blanc L, Falzon D, Fitzpatrick C, et al. Global Tuberculosis Control 2010. Geneva, Switzerland: World Health Organization, 2010. 16. Frieden TR, Sbarbaro JA. Promoting Adherence to Treatment for Tuberculosis: The Importance of Direct Observation. Bull World Health Organ 2007; 85:407-9. 17. Snider GL, Doctor L, Demas TA, Shaw AR. Obstructive Airway Disease in Patients with Treated Pulmonary Tuberculosis. Am Rev Respir Dis 1971; 103:625-40. 18. Pasipanodya JG, Miller TL, Vecino M, et al. Pulmonary Impairment after Tuberculosis. Chest 2007; 131:1817-24. 19. Chung KP, Chen JY, Lee CH, et al. Trends and Predictors of Changes in Pulmonary Function after Treatment for Pulmonary Tuberculosis. Clinics (Sao Paulo) 2011; 66:549-56. 20. Chang FY, Shi WY, Lin T, et al. Taiwan Tuberculosis Control Report 2010. Taipei: Centers for Disease Control, Department of Health, R.O.C (Taiwan), 2010. 21. Taiwan Tuberculosis Control Report: Centers for Disease Control, Taiwan, 2009. 22. Baker MA, Harries AD, Jeon CY, et al. The Impact of Diabetes on Tuberculosis Treatment Outcomes: A Systematic Review. BMC Med 2011; 9:81. 23. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and Challenges for Hiv Care in Overlapping Hiv and Tb Epidemics. JAMA 2008; 300:423-30. 24. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and Substance Abuse in the United States, 1997-2006. Arch Intern Med 2009; 169:189-97. 25. Kamboj M, Sepkowitz KA. The Risk of Tuberculosis in Patients with Cancer. Clin Infect Dis 2006; 42:1592-5. 26. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and Chronic Renal Disease. Semin Dial 2003; 16:38-44. 27. Ludvigsson JF, Wahlstrom J, Grunewald J, Ekbom A, Montgomery SM. Coeliac Disease and Risk of Tuberculosis: A Population Based Cohort Study. Thorax 2007; 62:23-8. 28. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid Use, Other Associated Factors, and the Risk of Tuberculosis. Arthritis Rheum 2006; 55:19-26. 29. Elkington P, Shiomi T, Breen R, et al. Mmp-1 Drives Immunopathology in Human Tuberculosis and Transgenic Mice. J Clin Invest 2011; 121:1827-33. 30. Pirkis JE, Speed BR, Yung AP, Dunt DR, MacIntyre CR, Plant AJ. Time to Initiation of Anti-Tuberculosis Treatment. Tuber Lung Dis 1996; 77:401-6. 31. Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix Metalloproteinases in Tuberculosis. Eur Respir J 2011; 38:456-64. 32. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix Metalloproteinase-9 Predicts Pulmonary Status Declines in Alpha1-Antitrypsin Deficiency. Respir Res 2011; 12:35. 33. Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis Treatment Effect on T-Cell Interferon-Gamma Responses to Mycobacterium Tuberculosis-Specific Antigens. Eur Respir J 2010; 36:355-61. 34. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Gold Executive Summary. Am J Respir Crit Care Med 2007; 176:532-55. 35. Theakston F. World Health Statistics. WHO press: Geneva, World Health Organization, 2008. 36. Lopez AD, Shibuya K, Rao C, et al. Chronic Obstructive Pulmonary Disease: Current Burden and Future Projections. Eur Respir J 2006; 27:397-412. 37. Salvi SS, Barnes PJ. Chronic Obstructive Pulmonary Disease in Non-Smokers. Lancet 2009; 374:733-43. 38. Behrendt CE. Mild and Moderate-to-Severe Copd in Nonsmokers: Distinct Demographic Profiles. Chest 2005; 128:1239-44. 39. Ehrlich RI, White N, Norman R, et al. Predictors of Chronic Bronchitis in South African Adults. Int J Tuberc Lung Dis 2004; 8:369-76. 40. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am J Respir Crit Care Med 2008; 177:19-26. 41. Shu CC, Wu HD, Yu MC, et al. Use of High-Dose Inhaled Corticosteroids Is Associated with Pulmonary Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease. Medicine (Baltimore) 2010; 89:53-61. 42. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. Am J Respir Crit Care Med 2011; 183:675-8. 43. Organization WH. Diabetes Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. . 2012. 44. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care 2004; 27:1047-53. 45. Vieillard-Baron A, Loubieres Y, Schmitt JM, Page B, Dubourg O, Jardin F. Cyclic Changes in Right Ventricular Output Impedance During Mechanical Ventilation. J Appl Physiol 1999; 87:1644-50. 46. Tsukaguchi K, Okamura H, Ikuno M, et al. [the Relation between Diabetes Mellitus and Ifn-Gamma, Il-12 and Il-10 Productions by Cd4+ Alpha Beta T Cells and Monocytes in Patients with Pulmonary Tuberculosis]. Kekkaku 1997; 72:617-22. 47. Stalenhoef JE, Alisjahbana B, Nelwan EJ, et al. The Role of Interferon-Gamma in the Increased Tuberculosis Risk in Type 2 Diabetes Mellitus. Eur J Clin Microbiol Infect Dis 2008; 27:97-103. 48. Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis Susceptibility of Diabetic Mice. Am J Respir Cell Mol Biol 2007; 37:518-24. 49. Spatz M, Eibl N, Hink S, et al. Impaired Primary Immune Response in Type-1 Diabetes. Functional Impairment at the Level of Apcs and T-Cells. Cell Immunol 2003; 221:15-26. 50. Leung CC, Lam TH, Chan WM, et al. Diabetic Control and Risk of Tuberculosis: A Cohort Study. Am J Epidemiol 2008; 167:1486-94. 51. Harries AD, Murray MB, Jeon CY, et al. Defining the Research Agenda to Reduce the Joint Burden of Disease from Diabetes Mellitus and Tuberculosis. Trop Med Int Health 2010; 15:659-63. 52. Lee CH, Lee MC, Lin HH, et al. Pulmonary Tuberculosis and Delay in Anti-Tuberculous Treatment Are Important Risk Factors for Chronic Obstructive Pulmonary Disease. PloS one 2012; 7:e37978. 53. Luh K-T. Taiwan Guidelines for Tb Diagnosis and Treatment. 4th ed. Taipei, Taiwan: Centers for Disease Control, R.O.C. (Taiwan), 2011. 54. Steen TW, Mazonde GN. Pulmonary Tuberculosis in Kweneng District, Botswana: Delays in Diagnosis in 212 Smear-Positive Patients. Int J Tuberc Lung Dis 1998; 2:627-34. 55. Lawn SD, Afful B, Acheampong JW. Pulmonary Tuberculosis: Diagnostic Delay in Ghanaian Adults. Int J Tuberc Lung Dis 1998; 2:635-40. 56. Chang CH, Shau WY, Jiang YD, et al. Type 2 Diabetes Prevalence and Incidence among Adults in Taiwan During 1999-2004: A National Health Insurance Data Set Study. Diabet Med 2010; 27:636-43. 57. Public Assistance Act. 7th ed. Taipei, Taiwan (R.O.C): Ministry of the Interior, 2010. 58. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for Atc Classification and Ddd Assignment. 14th ed., 2011. 59. Bateman ED, Hurd SS, Barnes PJ, et al. Global Strategy for Asthma Management and Prevention: Gina Executive Summary. Eur Respir J 2008; 31:143-78. 60. Copd Prevalence in 12 Asia-Pacific Countries and Regions: Projections Based on the Copd Prevalence Estimation Model. Respirology 2003; 8:192-8. 61. Wu CF, Feng NH, Chong IW, et al. Second-Hand Smoke and Chronic Bronchitis in Taiwanese Women: A Health-Care Based Study. BMC Public Health 2010; 10:44. 62. Hnizdo E, Singh T, Churchyard G. Chronic Pulmonary Function Impairment Caused by Initial and Recurrent Pulmonary Tuberculosis Following Treatment. Thorax 2000; 55:32-8. 63. Caballero A, Torres-Duque CA, Jaramillo C, et al. Prevalence of Copd in Five Colombian Cities Situated at Low, Medium, and High Altitude (Prepocol Study). Chest 2008; 133:343-9. 64. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary Tuberculosis Treated with Directly Observed Therapy: Serial Changes in Lung Structure and Function. Chest 1998; 113:933-43. 65. Garrigo M, Aragon LM, Alcaide F, et al. Multicenter Laboratory Evaluation of the Mb/Bact Mycobacterium Detection System and the Bactec Mgit 960 System in Comparison with the Bactec 460tb System for Susceptibility Testing of Mycobacterium Tuberculosis. J Clin Microbiol 2007; 45:1766-70. 66. Lin HH, Ezzati M, Chang HY, Murray M. Association between Tobacco Smoking and Active Tuberculosis in Taiwan: Prospective Cohort Study. Am J Respir Crit Care Med 2009; 180:475-80. 67. Shang S, Ordway D, Henao-Tamayo M, et al. Cigarette Smoke Increases Susceptibility to Tuberculosis--Evidence from in Vivo and in Vitro Models. J Infect Dis 2011; 203:1240-8. 68. Lee SW, Kim YS, Kim DS, Oh YM, Lee SD. The Risk of Obstructive Lung Disease by Previous Pulmonary Tuberculosis in a Country with Intermediate Burden of Tuberculosis. J Korean Med Sci 2011; 26:268-73. 69. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G. Human Polymorphonuclear Neutrophil Responses to Burkholderia Pseudomallei in Healthy and Diabetic Subjects. Infect Immun 2009; 77:456-63. 70. Geerlings SE, Hoepelman AI. Immune Dysfunction in Patients with Diabetes Mellitus (Dm). FEMS Immunol Med Microbiol 1999; 26:259-65. 71. Calverley PM, Walker P. Chronic Obstructive Pulmonary Disease. Lancet 2003; 362:1053-61. 72. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of Airflow Limitation Is Associated with Severity of Airway Inflammation in Smokers. Am J Respir Crit Care Med 1998; 158:1277-85. 73. Calverley P, Pauwels R, Vestbo J, et al. Combined Salmeterol and Fluticasone in the Treatment of Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial. Lancet 2003; 361:449-56. 74. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of Inhaled and Oral Corticosteroids and the Long-Term Risk of Cataract. Ophthalmology 2009; 116:652-7. 75. Lipworth BJ. Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-Analysis. Arch Intern Med 1999; 159:941-55. 76. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal Women. N Engl J Med 2001; 345:941-7. 77. Schleimer RP. Glucocorticoids Suppress Inflammation but Spare Innate Immune Responses in Airway Epithelium. Proc Am Thorac Soc 2004; 1:222-30. 78. Wang PH, Wang HC, Cheng PW, Cheng SL, Tsai CC. Hoarseness in Asthmatic Patients: The Side Effect of Inhaled Steroid or Not? J Asthma 2007; 44:823-6. 79. Davies L, Angus RM, Calverley PM. Oral Corticosteroids in Patients Admitted to Hospital with Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Randomised Controlled Trial. Lancet 1999; 354:456-60. 80. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941-7. 81. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of Nebulized Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Am J Respir Crit Care Med 2002; 165:698-703. 82. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The Role of Nebulised Budesonide in the Treatment of Exacerbations of Copd. Eur Respir J 2007; 29:660-7. 83. Bock NN, Sotir MJ, Parrott PL, Blumberg HM. Nosocomial Tuberculosis Exposure in an Outpatient Setting: Evaluation of Patients Exposed to Healthcare Providers with Tuberculosis. Infect Control Hosp Epidemiol 1999; 20:421-5. 84. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among Health-Care Workers in Low- and Middle-Income Countries: A Systematic Review. PLoS Med 2006; 3:e494. 85. Baker MA, Lin HH, Chang HY, Murray MB. The Risk of Tuberculosis Disease among Persons with Diabetes Mellitus: A Prospective Cohort Study. Clin Infect Dis 2012. 86. Baijal R, Praveenkumar HR, Amarapurkar DN, Nagaraj K, Jain M. Prevalence of Tuberculosis in Patients with Cirrhosis of Liver in Western India. Trop Doct 2010; 40:163-4. 87. Dobler CC, Flack JR, Marks GB. Risk of Tuberculosis among People with Diabetes Mellitus: An Australian Nationwide Cohort Study. BMJ Open 2012; 2:e000666. 88. Baker MA, Lin HH, Chang HY, Murray MB. The Risk of Tuberculosis Disease among Persons with Diabetes Mellitus: A Prospective Cohort Study. Clin Infect Dis 2012; 54:818-25. 89. Coker R, McKee M, Atun R, et al. Risk Factors for Pulmonary Tuberculosis in Russia: Case-Control Study. BMJ 2006; 332:85-7. 90. Shetty N, Shemko M, Vaz M, D'Souza G. An Epidemiological Evaluation of Risk Factors for Tuberculosis in South India: A Matched Case Control Study. Int J Tuberc Lung Dis 2006; 10:80-6. 91. Buskin SE, Gale JL, Weiss NS, Nolan CM. Tuberculosis Risk Factors in Adults in King County, Washington, 1988 through 1990. Am J Public Health 1994; 84:1750-6. 92. Perez A, Brown HS, 3rd, Restrepo BI. Association between Tuberculosis and Diabetes in the Mexican Border and Non-Border Regions of Texas. Am J Trop Med Hyg 2006; 74:604-11. 93. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, et al. Tuberculosis and Diabetes in Southern Mexico. Diabetes Care 2004; 27:1584-90. 94. Pablos-Mendez A, Blustein J, Knirsch CA. The Role of Diabetes Mellitus in the Higher Prevalence of Tuberculosis among Hispanics. Am J Public Health 1997; 87:574-9. 95. Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of Pulmonary Tuberculosis in Korean Civil Servants. Tuber Lung Dis 1995; 76:534-9. 96. Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in Poorly Controlled Type 2 Diabetes: Altered Cytokine Expression in Peripheral White Blood Cells. Clin Infect Dis 2008; 47:634-41. 97. Al-Attiyah RJ, Mustafa AS. Mycobacterial Antigen-Induced T Helper Type 1 (Th1) and Th2 Reactivity of Peripheral Blood Mononuclear Cells from Diabetic and Non-Diabetic Tuberculosis Patients and Mycobacterium Bovis Bacilli Calmette-Guerin (Bcg)-Vaccinated Healthy Subjects. Clin Exp Immunol 2009; 158:64-73. 98. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in Incidence of Diabetic End-Stage Renal Disease According to Race and Type of Diabetes. N Engl J Med 1989; 321:1074-9. 99. Harvey JN. Trends in the Prevalence of Diabetic Nephropathy in Type 1 and Type 2 Diabetes. Curr Opin Nephrol Hypertens 2003; 12:317-22. 100. Ayodele OE, Alebiosu CO, Salako BL. Diabetic Nephropathy--a Review of the Natural History, Burden, Risk Factors and Treatment. J Natl Med Assoc 2004; 96:1445-54. 101. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pract 2009; 15:540-59. 102. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R. Tuberculosis among Diabetics: The Philadelphia Survey. Am Rev Tuberc 1952; 65:1-50. 103. Swai AB, McLarty DG, Mugusi F. Tuberculosis in Diabetic Patients in Tanzania. Trop Doct 1990; 20:147-50. 104. Moss SE, Klein R, Klein BE. Risk Factors for Hospitalization in People with Diabetes. Arch Intern Med 1999; 159:2053-7. 105. SE. n. Clinical Practice. Management of Hyperglycemia in the Hospital Setting. N Engl J Med 2006; 355:1903-11. 106. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic Crises in Urban Blacks. Arch Intern Med 1997; 157:669-75. 107. Stead WW. Special Problems in Tuberculosis. Tuberculosis in the Elderly and in Residents of Nursing Homes, Correctional Facilities, Long-Term Care Hospitals, Mental Hospitals, Shelters for the Homeless, and Jails. Clin Chest Med 1989; 10:397-405. 108. Ramaswamy R, Corpuz M, Hewlett D. Tuberculosis Surveillance of Community Hospital Employees. A Recommended Strategy. Arch Intern Med 1995; 155:1637-9. 109. Asche C, LaFleur J, Conner C. A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes. Clin Ther 2011; 33:74-109. 110. Adams AS, Trinacty CM, Zhang F, et al. Medication Adherence and Racial Differences in A1c Control. Diabetes Care 2008; 31:916-21. 111. Donnelly LA, Morris AD, Evans JM. Adherence to Insulin and Its Association with Glycaemic Control in Patients with Type 2 Diabetes. QJM 2007; 100:345-50. 112. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical Outcomes and Adherence to Medications Measured by Claims Data in Patients with Diabetes. Diabetes Care 2004; 27:2800-5. 113. Bloomgarden ZT. Inflammation and Insulin Resistance. Diabetes Care 2003; 26:1922-6. 114. Comstock GW. Epidemiology of Tuberculosis. Am Rev Respir Dis 1982; 125:8-15. 115. Inghammar M, Ekbom A, Engstrom G, et al. Copd and the Risk of Tuberculosis--a Population-Based Cohort Study. PLoS One 2010; 5:e10138. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61653 | - |
dc.description.abstract | 由於抗生素藥物的進步,慢性非傳染性疾病已逐漸取代傳染病成為全球各地的主要死因。由於慢性疾病的本質上緩慢進展的特性使然,慢性非傳染性疾病和其相關的治療可以和傳染病產生長期的複雜的交互作用。若欲研究此交互作用,需要觀察很大的母群體,進行長時間的追蹤,受限於研究資源而不可行。以全球性的觀點切入,肺結核病是所有的傳染性疾病中造成最多死亡的重要疾病,在台灣也是重要的公衛議題。
台灣的全民健保是強制性的社會健康保險,納入全國超過96%的人口,自1996年實施以來,全面性的涵蓋所有的醫療照護。全民健保研究資料庫包含了全民健保歷年來所累積的健康資訊,經國家衛生研究院匯整後發行,非常適合用來研究慢性疾病間的交互作用。但是全民健保研究資料庫僅包含診斷碼和記帳資料,要在此資料庫中標定特定疾病診斷,需要特殊的方法以增加診斷的特異性和敏感性。本計劃建立了一個研究平台,可以提供臨床專家和資訊科技專家共同合作並有效率的溝通,我們應用此研究平台開發出臨床上重要的慢性疾病如慢性阻塞性肺病、糖尿病、肺結核以及相關共病的標定條件,並客觀量化相關的治療,進行時間相依的統計分析。 我們使用本研究平台,分析肺結核及其治療如何影響慢性阻塞性肺病的風險、慢性阻塞性肺病的治療藥物、以及糖尿病治療的醫囑遵從性對感染肺結核風險的影響,結果有重要的臨床發現,顯示本研究平台有很好的前曕性和效益。未來我們將再結合更多臨床領域的專家,擴展研究的範疇,進一步分析例如結核病復發的風險、公衛政策的效益評估、以及臨床工作人員院內曝觸結核感染等議題,使健保健康資訊的應用達到更大的研究效益。 | zh_TW |
dc.description.abstract | Chronic noncommunicable diseases (CNDs) have become the major cause of death and disabilities worldwide. Because of the nature course of these slowly progressing CNDs, the long-term interaction between the CNDs, their associated treatment and communicable disease (CDs) is complex. It requires large cohort with very long period of follow-up to investigate these interaction. Among the CDs, the pulmonary tuberculosis (TB) is the leading cause of death worldwide and also an important issue in public health in Taiwan.
The National Health Insurance (NHI) is a mandatory nationwide health insurance program, offering comprehensive medical care coverage to more than 96% of Taiwanese residents since 1996. The NHI research database (NHIRD) provides a nationwide population suitable for such studies. However, the NHIRD contains only claim data and requires special approach to define the diagnoses of CNDs when compared with classical cohort study. We established a study platform using NHIRD and developed comprehensive diagnostic criteria for pulmonary TB and important CNDs such as chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM) and other co-morbidities. The investigation on the long-term interaction between the pulmonary TB, DM, and COPD showed promising results. Future works to extend the scope of the present study platform to address the issues such as TB recurrence, efficacy of public health policy, and nosocomial hazard for health care workers will be done. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:08:33Z (GMT). No. of bitstreams: 1 ntu-102-D99945016-1.pdf: 4792328 bytes, checksum: de81b2df905c3c4ad7b594bc4e4c67e5 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Chapter 1: Introduction 1
1.1 The National Health Insurance Research Database (NHIRD) of Taiwan 2 1.2 Pulmonary Tuberculosis (TB) 4 1.3 Chronic obstructive pulmonary disease (COPD) 5 1.4 Diabetes Mellitus (DM) 7 1.5 Purpose and Importance of the Present Study 8 Chapter 2: Material and Methods 10 2.1 Translating and Indexing the NHIRD 10 2.2 Identifying Pulmonary TB in NHIRD 11 2.3 Identifying COPD in NHIRD 12 2.4 Identifying DM in NHIRD 14 2.5 Identifying Other Comorbidities and Low Income Status in NHIRD 14 2.6 Control Subjects Selection 15 2.7 Statistics 18 Chpater 3: Results 21 3.1 Part I: Impact of Pulmonary TB on the Risk of COPD 21 3.2 Part II: The Impact of COPD Medication on the Risk of TB 31 3.3 Part III: The Impact of DM Control on Developing Pulmonary TB 41 Chapter 4: Discussion 49 4.1 Part I: Impact of Pulmonary TB on the Risk of COPD 49 4.2 Part II: The Impact of COPD Medication on the Risk of Pulmonary TB 54 4.3 Part III: The Impact of DM Control on Developing TB 60 Chpater 5: Conclusions and Future Work 66 References 69 Related Publications 85 | |
dc.language.iso | en | |
dc.title | 以全民健康保險資料庫研究肺結核病與慢性非傳染性疾病之長期交互作用 | zh_TW |
dc.title | Investigating the Long-Term Interaction among Pulmonary Tuberculosis and Chronic Noncommunicable Diseases with the Taiwan National Health Insurance Research Database | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 賴飛羆(Feipei Lai),歐陽彥正(Yen-Jen Oyang,),張瑞峰(Ruey-Feng Chang),傅楸善(Chiou-Shann Fuh),王振源(Jann-Yuan Wang) | |
dc.subject.keyword | 肺結核,慢性阻塞性肺病,糖尿病,臺灣全民健保資料庫, | zh_TW |
dc.subject.keyword | pulmonary tuberculosis,chronic obstructive pulmonary disease,diabetes mellitus,Taiwan National Health Insurance Research Database, | en |
dc.relation.page | 87 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-01 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 4.68 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。